Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long Term Safety of OTX-TP in Glaucoma and Ocular Hypertension
NCT04061044Phase 3Completed
- Sponsor
- Ocular Therapeutix
- Start
- Jul 2018
- Primary completion
- Feb 2020
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of travoprost in open-angle glaucoma (OAG) and ocular hypertension, sponsored by Ocular Therapeutix. Primary endpoint: Incidence of Treatment-Related Adverse Events (Safety and Tolerability) at 12 months. Started Jul 2018; status: completed.
02
Drugs
travoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on NCT04061044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04061044.